✦ LIBER ✦

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

✍ Scribed by Sternberg, Cora N.; Hawkins, Robert E.; Wagstaff, John; Salman, Pamela; Mardiak, Jozef; Barrios, Carlos H.; Zarba, Juan J.; Gladkov, Oleg A.; Lee, Eunsik; Szczylik, Cezary; McCann, Lauren; Rubin, Stephen D.; Chen, Mei; Davis, Ian D.

Book ID: 120372398
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 293 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.12.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: A Randomised, Double-Blind Phase III

Re: A Randomised, Double-Blind Phase III Study of Pazopanib in Patients with Advanced and/or Metastatic Renal Cell Carcinoma: Final Overall Survival Results and Safety Update

✍ Laguna, M. Pilar 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 55 KB

Re: Pazopanib in Locally Advanced or Met

Re: Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

✍ Taneja, Samir S. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

7106 Predictive and prognostic factors i

7106 Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC)

✍ Sternberg, C.; Davis, I.; Wagstaff, J.; Hawkins, R.; Chen, M.; Ding, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

7119 Genitourinary malignancies – Renal

7119 Genitourinary malignancies – Renal cancer Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial

✍ Hawkins, R.; Hodge, R.; Chen, M.; Neary, M.; Pickard, A.S.; Sternberg, C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

Efficacy and safety of sorafenib in pati

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

✍ Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 195 KB

## Background: Most cases of hepatocellular carcinoma occur in the asia-pacific region, where chronic hepatitis b infection is an important aetiological factor. assessing the efficacy and safety of new therapeutic options in an asia-pacific population is thus important. we did a multinational phase